CPLX1

Across TCGA pan-cancer cohorts, CPLX1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CPLX1 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher CPLX1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CPLX1 expression acts as an unfavorable survival marker.

CHOL, SARC, and UCEC are the cancer types where CPLX1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.024	0.728	<.001	36	view →
SARC	DFS	Median	All	0.096	0.611	.005	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CPLX1–CHOL (OS)

Open the CHOL breakdown →